Update from COMED’s Pancreatic Cancer Pipeline:
Fresh preliminary data from animal studies indicates that treatment with our patented COMED Hooks platform achieved significantly slower tumor growth compared to control groups. A promising signal as this program advances.
Progress at this pace is only possible thanks to our partners. Icosagen AS (Estonia) supports antibody engineering and production of COMED Hooks-002, while Charles River Laboratories (Germany) ensures the highest standards in preclinical testing with their deep experience in regulatory readiness.
Advancing together, we are building the path forward for next-generation antibody therapeutics.